These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21947370)

  • 1. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis.
    Wang B; Lau YY; Liang M; Vainshtein I; Zusmanovich M; Lu H; Magrini F; Sleeman M; Roskos L
    J Clin Pharmacol; 2012 Aug; 52(8):1150-61. PubMed ID: 21947370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
    Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy.
    Nair JR; Edwards SW; Moots RJ
    Expert Opin Biol Ther; 2012 Dec; 12(12):1661-8. PubMed ID: 23094973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.
    Campbell J; Nys J; Eghobamien L; Cohen ES; Robinson MJ; Sleeman MA
    MAbs; 2016 Oct; 8(7):1398-1406. PubMed ID: 27560702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
    Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
    Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients.
    Mortensen JH; Guo X; De Los Reyes M; Dziegiel MH; Karsdal MA; Bay-Jensen AC; White WI
    Clin Exp Rheumatol; 2019; 37(1):73-80. PubMed ID: 30418117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells.
    Yamada T; Sun Q; Zeibecoglou K; Bungre J; North J; Kay AB; Lopez AF; Robinson DS
    J Allergy Clin Immunol; 1998 May; 101(5):677-82. PubMed ID: 9600506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.
    Crotti C; Raimondo MG; Becciolini A; Biggioggero M; Favalli EG
    Drug Des Devel Ther; 2017; 11():211-223. PubMed ID: 28144129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.
    Mould DR; Davis CB; Minthorn EA; Kwok DC; Elliott MJ; Luggen ME; Totoritis MC
    Clin Pharmacol Ther; 1999 Sep; 66(3):246-57. PubMed ID: 10511060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis.
    Crotti C; Biggioggero M; Becciolini A; Agape E; Favalli EG
    Expert Opin Investig Drugs; 2019 Jul; 28(7):573-581. PubMed ID: 31208237
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.
    Cook AD; Hamilton JA
    Ther Adv Musculoskelet Dis; 2018 Feb; 10(2):29-38. PubMed ID: 29387176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
    Ng CM; Bruno R; Combs D; Davies B
    J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.
    Wang B; Wu CY; Jin D; Vicini P; Roskos L
    CPT Pharmacometrics Syst Pharmacol; 2018 Jan; 7(1):5-15. PubMed ID: 28836356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.
    Di Franco M; Gerardi MC; Lucchino B; Conti F
    Core Evid; 2014; 9():41-8. PubMed ID: 24648832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.